Clinical usefulness of fecal calprotectin in assessing disease activity and endoscopic remission in intestinal Behçet’s disease
Intestinal Research · 31.10.2026 · 24 (4) · 735-743
DOI: 10.5217/ir.2025.00267 ↗Kurz gefasst
Fachartikel in der Zeitschrift Intestinal Research, erschienen am 31.10.2026. Verfasst von Woojin Ahn und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background/Aims: Intestinal Behçet’s disease (BD) is a manifestation of BD involving the gastrointestinal tract. Although fecal calprotectin (FC) is a useful inflammatory marker, its role in intestinal BD is unclear.
Methods
We retrospectively analyzed 78 patients with intestinal BD to evaluate correlations between FC levels and the Disease Activity Index for Intestinal Behçet’s Disease (DAIBD), C-reactive protein (CRP), and erythrocyte sedimentation rate. FC and CRP levels were compared between patients in endoscopic remission and those with active disease. Receiver operating characteristic (ROC) curve analysis was used to evaluate FC’s ability to predict endoscopic activity and ulcer size.
Results
FC levels significantly correlated with DAIBD scores (r= 0.253, P= 0.025) and CRP (r= 0.227, P= 0.046). Patients with endoscopically active disease had higher FC (1,124 ± 1,957 μg/g vs. 367 ± 1,208 μg/g; P< 0.001) and CRP levels (16.0 ± 23.7 mg/L vs. 14.4 ± 46.5 mg/L; P= 0.027) than those in remission. Patients with larger ulcers ( ≥ 30 mm) had higher FC levels than those with smaller ulcers (2,212 ± 2,609 μg/g vs. 962 ± 1,822 μg/g; P= 0.034). An FC cutoff level of 176 μg/g discriminated active endoscopic disease (sensitivity 59.3%, specificity 83.3%), with an area under the ROC curve (AUC) of 0.724 (95% confidence interval, 0.605–0.843; P= 0.002), outperforming CRP (AUC, 0.657).
Conclusions
FC levels correlated with DAIBD scores and endoscopic inflammation in intestinal BD. FC outperformed CRP in detecting endoscopic activity, supporting its use in disease management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
- Institute of Gastroenterology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
- Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. wisdompark@yuhs.ac.
- Institute of Gastroenterology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. wisdompark@yuhs.ac.
- Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. geniushee@yuhs.ac.
- Institute of Gastroenterology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. geniushee@yuhs.ac.
Zitieren
APA
Ahn, W., Choi, S., Han, S. J., Park, S. J., Park, J. J., Kim, T. I., Park, J., & Cheon, J. H. (2026). Clinical usefulness of fecal calprotectin in assessing disease activity and endoscopic remission in intestinal Behçet’s disease. Intestinal Research, 24(4), 735-743. https://doi.org/10.5217/ir.2025.00267
Vancouver
Ahn W, Choi S, Han SJ, Park SJ, Park JJ, Kim TI, et al. Clinical usefulness of fecal calprotectin in assessing disease activity and endoscopic remission in intestinal Behçet’s disease. Intestinal Research. 2026;24(4):735-743. doi:10.5217/ir.2025.00267
BibTeX
@article{Ahn2026,
author = {Ahn, Woojin and Choi, Seoyoon and Han, So Jung and Park, Soo Jung and Park, Jae Jun and Kim, Tae Il and Park, Jihye and Cheon, Jae Hee},
title = {Clinical usefulness of fecal calprotectin in assessing disease activity and endoscopic remission in intestinal Behçet’s disease},
journal = {Intestinal Research},
year = {2026},
volume = {24},
number = {4},
pages = {735--743},
doi = {10.5217/ir.2025.00267}
}
EUVIMED